Publications by authors named "Matthew R Peery"
Article Synopsis
- - The objective of the review was to examine the pharmacology, safety, and effectiveness of BCMA-directed immunotherapies, such as CAR-T therapy and bispecific antibodies, for treating relapsed/refractory multiple myeloma (RRMM).
- - Evidence from phase III and II clinical trials shows that BCMA-directed therapies like idecabtagene vicleucel and teclistamab significantly improve response rates and progression-free survival compared to standard treatments for RRMM.
- - Despite their benefits, these therapies pose safety risks (like cytokine release syndrome) and face challenges in patient access due to the need for specialized administration and monitoring facilities.
Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first line chemoimmunotherapy, necessitating second-line salvage therapy. This has historically consisted of platinum-based chemotherapy regimens followed by autologous hematopoietic stem cell transplantation with curative intent for transplant-eligible patients or palliative chemotherapy for transplant-ineligible patients.
View Article and Find Full Text PDF